Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18)
In this real-world, 18-month cohort, empagliflozin produced more pronounced improvements in albuminuria and a slightly greater absolute reduction in HbA1c, whereas semaglutide showed a trend toward greater weight loss, though not statistically significant. These findings emphasize individualized therapy choices in T2DM based on cardiorenal risk profiles and underscore the potential value of early empagliflozin initiation, especially in patients at higher risk of renal deterioration.
Authors
- Dillon Trujillo (ORCID: https://orcid.org/0000-0001-7990-1909)
- Marisol Badiel (ORCID: https://orcid.org/0000-0003-2644-9319)
- William Martínez (ORCID: https://orcid.org/0000-0002-3155-4386)
- Alín Abreu Lomba (ORCID: https://orcid.org/0000-0002-7377-4969)
- David Aristizabal-Colorado
- S. Castillo
Institutions
- Universidad de Antioquia (CO)
- Deaconess Clinic (US)
- Fundación Universitaria del Área Andina (CO)
- Universidad de Medellín (CO)
- Clínica CES (CO)
- Universidad Libre de Colombia (CO)
Publication Details
- Journal
- Cureus
- Published
- 2025-05-03
- DOI
- https://doi.org/10.7759/cureus.83416
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00